Supplement

You have full text access to this OnlineOpen article

Incidence of in situ and invasive vulvar cancer in the US, 1998–2003†‡§

  1. Mona Saraiya MD, MPH1,¶,*,
  2. Meg Watson MPH1,
  3. Xiaocheng Wu MD, MPH2,
  4. Jessica B. King MPH1,
  5. Vivien W. Chen PhD2,
  6. Jennifer S. Smith PhD3,‖,
  7. Anna R. Giuliano PhD4,††

Article first published online: 3 NOV 2008

DOI: 10.1002/cncr.23759

Issue

Cancer

Cancer

Supplement: Assessing the Burden of HPV-Associated Cancers in the United States

Volume 113, Issue Supplement 10, pages 2865–2872, 15 November 2008

Additional Information

How to Cite

Saraiya, M., Watson, M., Wu, X., King, J. B., Chen, V. W., Smith, J. S. and Giuliano, A. R. (2008), Incidence of in situ and invasive vulvar cancer in the US, 1998–2003. Cancer, 113: 2865–2872. doi: 10.1002/cncr.23759

Author Information

  1. 1

    Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia

  2. 2

    Louisiana Tumor Registry and Epidemiology Program, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, Louisiana

  3. 3

    Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina

  4. 4

    Risk Assessment, Detection, and Intervention Program, The Moffitt Cancer Center and Research Institute, Tampa, Florida

  1. Fax: (770) 488-4639.

  2. ‖

    Dr. Smith has received research grants, honoraria, and consulting fees from GlaxoSmithKline and Merck Corporation.

  3. ††

    Dr. Giuliano has acted as a member of the Speakers Bureau and Advisory Board for Merck and Company, and has received a research grant from the company.

*Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, 4770 Buford Highway, NE, MS K-55, Atlanta, GA 30341

  1. †

    For more information on vulvar cancers, please visit www.cdc.gov/cancer/gynecologic

  2. ‡

    The findings and conclusions of this article are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.

  3. §

    This article is a US Government work and, as such, is in the public domain in the United States of America.

Publication History

  1. Issue published online: 3 NOV 2008
  2. Article first published online: 3 NOV 2008
  3. Manuscript Accepted: 22 MAY 2008
  4. Manuscript Revised: 7 MAY 2008
  5. Manuscript Received: 14 APR 2008

Funded by

  • Cooperative Agreement. Grant Number: U50 DP424071-04
  • Centers for Disease Control and Prevention

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (149K)

REFERENCES

  • 1
    Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006; 118: 3030–3044.
    Direct Link:
  • 2
    U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999-2004 Incidence and Mortality Web-Based Report. Bethesda, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2007. Available at: www.cdc.gov/uscs. Accessed on July 15, 2008.
  • 3
    Madeleine MM,Daling JR. Cancers of the vulva and vagina. In: ShottenfeldD,FraumeniJF, eds. Cancer Epidemiology and Prevention.3rd ed. New York: Oxford University Press; 2006: 1068–1074.
  • 4
    Schiffman M,Kjaer SK. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr. 2003;( 31): 14–19.
  • 5
    Srodon M,Stoler MH,Baber GB,Kurman RJ. The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN). Am J Surg Pathol. 2006; 30: 1513–1518.
  • 6
    Cogliano V. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Human Papillomavirus [90]. Lyon, France: International Agency for Research on Cancer; 2007.
  • 7
    Hoots B,Kurman R,Smith JS. Human papillomavirus type distribution in vaginal and vulvar cancers and their precursors: a meta-analysis. Presented at the International Papillomavirus Virus Conference, Beijing, China, November 2007.
  • 8
    Hampl M,Sarajuuri H,Wentzensen N,Bender HG,Kueppers V. Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer. Obstet Gynecol. 2006; 108: 1361–1368.
  • 9
    Judson PL,Habermann EB,Baxter NN,Durham SB,Virnig BA. Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol. 2006; 107: 1018–1022.
  • 10
    Watson M,Saraiya M,Ahmed F, et al. U sing population-based cancer registry data to assess the burden of human papillomavirus-associated cancers in the United States: overview of methdos. Cancer. 2008; 113( 10 suppl): 2841–2854.
    Direct Link:
  • 11
    Kurman RJ,Toki T,Schiffman MH. Basaloid and warty carcinomas of the vulva. Distinctive types of squamous cell carcinoma frequently associated with human papillomaviruses. Am J Surg Pathol. 1993; 17: 133–145.
  • 12
    Madeleine MM,Daling JR,Carter JJ, et al. Cofactors with human papillomavirus in a population-based study of vulvar cancer. J Natl Cancer Inst. 1997; 89: 1516–1523.
  • 13
    Brinton LA,Nasca PC,Mallin K,Baptiste MS,Wilbanks GD,Richart RM. Case-control study of cancer of the vulva. Obstet Gynecol. 1990; 75: 859–866.
  • 14
    Daling JR,Sherman KJ,Hislop TG, et al. Cigarette smoking and the risk of anogenital cancer. Am J Epidemiol. 1992; 135: 180–189.
  • 15
    Frisch M,Goodman MT. Human papillomavirus-associated carcinomas in Hawaii and the mainland U.S. Cancer. 2000; 88: 1464–1469.
    Direct Link:
  • 16
    Chaturvedi AK,Engels EA,Gilbert ES, et al. Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst. 2007; 99: 1634–1643.
  • 17
    Balamurugan A,Ahmed F,Saraiya M, et al. Potential role of human papillomavirus in the development of subsequent primary in situ and invasive cancers among cervical cancer survivors. Cancer. 2008; 113( 10 suppl): 2919–2925.
    Direct Link:
  • 18
    Kleinerman R,Kosary CL,Hildesheim A. New malignancies following cancer of the cervix uteri, vagina, and vulva. In: CurtisRE,FreedmanDM,RiesLAG, et al, eds. New Malignancies Among Cancer Survivors. NIH Pub. No. 05-5302. SEER Cancer Registries, 1973-2000. Bethesda, MD: National Cancer Institute; 2006: 207–229
  • 19
    Sideri M,Jones RW,Wilkinson EJ, et al. Squamous vulvar intraepithelial neoplasia: 2004 modified terminology, ISSVD Vulvar Oncology Subcommittee. J Reprod Med. 2005; 50: 807–810.
  • 20
    Scurry J,Wilkinson EJ. Review of terminology of precursors of vulvar squamous cell carcinoma. J Low Genit Tract Dis. 2006; 10: 161–169.
  • 21
    Markowitz LE,Dunne EF,Saraiya M,Lawson HW,Chesson H, Unger ER; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007; 56: 1–24.
  • 22
    Joura EA,Leodolter S,Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of 3 randomised clinical trials. Lancet. 2007; 369: 1693–1702.
View Full Article (HTML) Get PDF (149K)